Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05701488
Title SIRT With Tremelimumab and Durvalumab for Resectable HCC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jiping Wang, MD, PhD
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.